OncoGenex Pharmaceuticals, Inc.
) recently announced that it is looking to move its oncology
candidate, OGX-427, into a phase II study, Borealis-2, for the
potential treatment of advanced or metastatic bladder cancer.
The investigator-sponsored, randomized, controlled phase II
study will enroll 200 patients suffering from advanced or
metastatic bladder cancer whose disease has progressed following
initial platinum-based chemotherapy treatment.
FURIEX PHARMACT (FURX): Free Stock Analysis
ONCOGENEX PHARM (OGXI): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.
This study will evaluate OGX-427 plus
) Taxotere (docetaxel) in improving survival compared to Taxotere
OGX-427 is also in another clinical trial, Borealis-1. A
randomized, placebo-controlled phase II study, Borealis-1 is
designed to evaluate the potential survival benefit, safety and
tolerability of combining OGX-427 with gemcitabine and cisplatin
in the first-line treatment of patients with advanced bladder
OncoGenex will decide on a phase III study of OGX-427 in bladder
cancer if one of these two studies shows a survival advantage.
The most advanced candidate in OncoGenex's pipeline is custirsen
(phase III) under evaluation for the treatment of metastatic
castrate-resistant prostate cancer in men and also for the
treatment of patients with advanced, unresectable non-small cell
lung cancer. OncoGenex has a global collaboration and license
Teva Pharmaceutical Industries Ltd.
) to develop and commercialize the candidate. Another candidate,
OGX-225, for the solid tumors indication is in pre-clinical
OncoGenex and Teva currently carry a Zacks Rank #3 (Hold). Right
Furiex Pharmaceuticals, Inc.
) looks more attractive with a Zacks Rank #1 (Strong Buy).